JAKs and STATs in Immunity, Immunodeficiency, and Cancer

STATs in cancer inflammation and immunity: a leading role for STAT3

Yu, H., Pardoll, D., & Jove, R. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2734 · Cited by 4,383

Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders

Baxter, E. J., Scott, L. M., Campbell, P. J., East, C., Fourouclas, N., Swanton, S., Vassiliou, G. S., Bench, A. J., Boyd, E. M., Curtin, N., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)71142-9 · Cited by 3,548

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

James, C., Ugo, V., Couedic, J. P. L., Staerk, J., Delhommeau, F., Lacout, C., Garçon, L., Raslová, H., Berger, R., Griscelli, A. B., et al. (2005) · Nature · doi:10.1038/nature03546 · Cited by 3,542

A Gain-of-Function Mutation of JAK2 in Myeloproliferative Disorders

Kralovics, R., Passamonti, F., Buser, A. S., Teo, S.-S., Tiedt, R., Passweg, J. R., Tichelli, A., Cazzola, M., & Skoda, R. C. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051113 · Cited by 3,470

A Genome-Wide Association Study Identifies IL23R as an Inflammatory Bowel Disease Gene

Duerr, R. H., Taylor, K. D., Brant, S. R., Rioux, J. D., Silverberg, M. S., Daly, M. J., Steinhart, A. H., Abraham, C., Regueiro, M., Griffiths, A., et al. (2006) · Science · doi:10.1126/science.1135245 · Cited by 3,039

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

Levine, R. L., Wadleigh, M., Cools, J., Ebert, B. L., Wernig, G., Huntly, B. J. P., Boggon, T. J., Wlodarska, I., Clark, J. J., Moore, S., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.03.023 · Cited by 2,993

A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis

Verstovsek, S., Mesa, R. A., Gotlib, J., Levy, R. S., Gupta, V., DiPersio, J. F., Catalano, J. V., Deininger, M., Miller, C., Silver, R. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1110557 · Cited by 2,103

JAKS AND STATS: Biological Implications

Leonard, W. J., & O’Shea, J. J. (1998) · Annual Review of Immunology · doi:10.1146/annurev.immunol.16.1.293 · Cited by 1,826

JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis

Harrison, C., Kiladjian, J.-J., Al-Ali, H. K., Gisslinger, H., Waltzman, R., Stalbovskaya, V., McQuitty, M., Hunter, D. S., Levy, R., Knoops, L., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1110556 · Cited by 1,825

The genetic basis of early T-cell precursor acute lymphoblastic leukaemia

Zhang, J., Ding, L., Holmfeldt, L., Wu, G., Heatley, S. L., Payne-Turner, D., Easton, J., Chen, X., Wang, J., Rusch, M., et al. (2012) · Nature · doi:10.1038/nature10725 · Cited by 1,596

The JAK-STAT Pathway at Twenty

Stark, G. R., & Darnell, J. E., Jr. (2012) · Immunity · doi:10.1016/j.immuni.2012.03.013 · Cited by 1,577

Oncogenically active MYD88 mutations in human lymphoma

Ngo, V. N., Young, R. M., Schmitz, R., Jhavar, S. G., Xiao, W., Lim, K., Kohlhammer, H., Xu, W., Yang, Y., Zhao, H., et al. (2010) · Nature · doi:10.1038/nature09671 · Cited by 1,560

Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia

Puente, X. S., Pinyol, M., Quesada, V., Conde, L., Ordóñez, G. R., Villamor, N., Escaramís, G., Jares, P., Beà, S., González, M., et al. (2011) · Nature · doi:10.1038/nature10113 · Cited by 1,529

Interleukin-2 Signaling via STAT5 Constrains T Helper 17 Cell Generation

Laurence, A., Tato, C. M., Davidson, T. S., Kanno, Y., Chen, Z., Yao, Z., Blank, R. B., Meylan, F., Siegel, R., Hennighausen, L., et al. (2007) · Immunity · doi:10.1016/j.immuni.2007.02.009 · Cited by 1,507

MPLW515L Is a Novel Somatic Activating Mutation in Myelofibrosis with Myeloid Metaplasia

Pikman, Y., Lee, B. H., Mercher, T., McDowell, E. P., Ebert, B. L., Gozo, M. C., Cuker, A. C., Wernig, G., Moore, S. A., Galinsky, I. A., et al. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030270 · Cited by 1,445

JAK2 Exon 12 Mutations in Polycythemia Vera and Idiopathic Erythrocytosis

Scott, L. M., Tong, W., Levine, R. L., Scott, M., Beer, P., Stratton, M. R., Futreal, P., Erber, W., McMullin, M., Harrison, C. N., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065202 · Cited by 1,346

MYD88 L265P Somatic Mutation in Waldenström's Macroglobulinemia

Treon, S. P., Xu, L., Yang, G., Zhou, Y., Liu, X., Cao, Y., Sheehy, P. S., Manning, R. J., Patterson, C. J., Tripsas, C. K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200710 · Cited by 1,316

STAT3 Mutations in the Hyper-IgE Syndrome

Holland, S. M., DeLeo, F. R., Elloumi, H. Z., Hsu, A. P., Uzel, G., Brodsky, N. N., Freeman, A. F., Demidowich, A. P., Davis, J., Turner, M. L. C., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa073687 · Cited by 1,233

NF-κB and STAT3 – key players in liver inflammation and cancer

He, G., & Karin, M. (2010) · Cell Research · doi:10.1038/cr.2010.183 · Cited by 1,223

Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis

Verstovšek, S., Kantarjian, H. M., Mesa, R. A., Pardanani, A. D., Cortes, J. E., Thomas, D. A., Estrov, Z. E., Fridman, J. S., Bradley, E. C., Erickson‐Viitanen, S., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002028 · Cited by 1,165

Impaired TH17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome

Milner, J. D., Brenchley, J. M., Laurence, A., Freeman, A. F., Hill, B. J., Elias, K. M., Kanno, Y., Spalding, C., Elloumi, H. Z., Paulson, M. L., et al. (2008) · Nature · doi:10.1038/nature06764 · Cited by 1,157

SF3B1 and Other Novel Cancer Genes in Chronic Lymphocytic Leukemia

Wang, L., Lawrence, M. S., Wan, Y., Stojanov, P., Sougnez, C. L., Stevenson, K. E., Werner, L. L., Sivachenko, A., DeLuca, D. S., Zhang, L., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1109016 · Cited by 1,103

Dominant-negative mutations in the DNA-binding domain of STAT3 cause hyper-IgE syndrome

Minegishi, Y., Saitō, M., Tsuchiya, S., Tsuge, I., Takada, H., Hara, T., Kawamura, N., Ariga, T., Pašić, S., Stojković, O., et al. (2007) · Nature · doi:10.1038/nature06096 · Cited by 1,075

STAT4 and the Risk of Rheumatoid Arthritis and Systemic Lupus Erythematosus

Remmers, E. F., Plenge, R. M., Lee, A. T., Graham, R., Hom, G., Behrens, T. W., de Bakker, P. I. W., Le, J. M., Lee, H., Batliwalla, F., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa073003 · Cited by 1,055

Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis

Fleischmann, R., Kremer, J. M., Cush, J. J., Schulze‐Koops, H., Connell, C. A., Bradley, J. D., Gruben, D. C., Wallenstein, G. V., Zwillich, S. H., & Kanik, K. S. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109071 · Cited by 1,028

Requirement of STAT5b for sexual dimorphism of body growth rates and liver gene expression

Udy, G. B., Towers, R. P., Snell, R. G., Wilkins, R. J., Park, S.-H., Ram, P. A., Waxman, D. J., & Davey, H. W. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.14.7239 · Cited by 991

Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis

van Vollenhoven, R., Fleischmann, R., Cohen, S. B., Lee, E. B., Meijide, J. A. G., Wagner, S., Forejtová, Š., Zwillich, S. H., Gruben, D. C., Koncz, T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112072 · Cited by 947

Enhanced DNA-Binding Activity of a Stat3-Related Protein in Cells Transformed by the Src Oncoprotein

Yu, C.-L., Meyer, D. J., Campbell, G. S., Larner, A. C., Carter-Su, C., Schwartz, J., & Jove, R. (1995) · Science · doi:10.1126/science.7541555 · Cited by 931

Stat proteins and oncogenesis

Bromberg, J. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15617 · Cited by 863

Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis

Liu, L., Okada, S., Kong, X., Kreins, A. Y., Cypowyj, S., Abhyankar, A., Toubiana, J., Itan, Y., Audry, M., Nitschké, P., et al. (2011) · The Journal of Experimental Medicine · doi:10.1084/jem.20110958 · Cited by 816

Impaired response to interferon-α/β and lethal viral disease in human STAT1 deficiency

Boisson‐Dupuis, S., Jouanguy, E., Al-Hajjar, S. H., Fieschi, C., Al-Mohsen, I. Z., Aljumaah, S., Yang, K., Chapgier, A. L. A., Eidenschenk, C., Eid, P., et al. (2003) · Nature Genetics · doi:10.1038/ng1097 · Cited by 814

Hyper-IgE Syndrome with Recurrent Infections — An Autosomal Dominant Multisystem Disorder

Grimbacher, B., Holland, S. M., Gallin, J. I., Greenberg, F., Hill, S. C., Malech, H. L., Miller, J., O’Connell, A. C., & Puck, J. M. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903043400904 · Cited by 801

Tofacitinib, an Oral Janus Kinase Inhibitor, in Active Ulcerative Colitis

Sandborn, W. J., Ghosh, S. K., Panés, J., Vranic, I. I., Su, C. G., Rousell, S., & Niezychowski, W. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112168 · Cited by 800

Somatic STAT3 Mutations in Large Granular Lymphocytic Leukemia

Rajala, H. L. M., Eldfors, S., Ellonen, P., van Adrichem, A. J., Kuusanmäki, H. A., Andersson, E. I., Lagström, S., Clemente, M. J., Olson, T. L., Jalkanen, S. E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1114885 · Cited by 791

Human Tyrosine Kinase 2 Deficiency Reveals Its Requisite Roles in Multiple Cytokine Signals Involved in Innate and Acquired Immunity

Minegishi, Y., Saitō, M., Morio, T., Watanabe, K., Agematsu, K., Tsuchiya, S., Takada, H., Hara, T., Kawamura, N., Ariga, T., et al. (2006) · Immunity · doi:10.1016/j.immuni.2006.09.009 · Cited by 701

STAT1 Mutations in Autosomal Dominant Chronic Mucocutaneous Candidiasis

van de Veerdonk, F. L., Plantinga, T. S., Hoischen, A., Smeekens, S. P., Joosten, L. A. B., Gilissen, C., Arts, P., Rosentul, D. C., Carmichael, A., der Graaf, C. A. A. S.-V., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1100102 · Cited by 684

Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Behçet's disease

Remmers, E. F., Coşan, F., Kirino, Y., Ombrello, M. J., Abacı, N., Satorius, C. L., Le, J. M., Yang, B. C., Korman, B. D., Çakiris, A., et al. (2010) · Nature Genetics · doi:10.1038/ng.625 · Cited by 678

Deficiency of Th17 cells in hyper IgE syndrome due to mutations in STAT3

Ma, C. S., Chew, G. Y. J., Simpson, N., Priyadarshi, A., Wong, M., Grimbacher, B., Fulcher, D. A., Tangye, S. G., & Cook, M. C. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20080218 · Cited by 652

Modulation of Innate and Adaptive Immune Responses by Tofacitinib (CP-690,550)

Ghoreschi, K., Jesson, M. I., Xiong, L., Lee, J. L., Ghosh, S., Alsup, J. W., Warner, J. D., Tanaka, M., Steward-Tharp, S. M., Gadina, M., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003668 · Cited by 651

STAT proteins: novel molecular targets for cancer drug discovery

Turkson, J., & Jove, R. (2000) · Oncogene · doi:10.1038/sj.onc.1204086 · Cited by 643

JAK2 phosphorylates histone H3Y41 and excludes HP1α from chromatin

Dawson, M. A., Bannister, A. J., Göttgens, B., Foster, S. D., Bartke, T., Green, A. R., & Kouzarides, T. (2009) · Nature · doi:10.1038/nature08448 · Cited by 624

Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor

Changelian, P. S., Flanagan, M. E., Ball, D. J., Kent, C. R., Magnuson, K. S., Martin, W. H., Rizzuti, B. J., Sawyer, P. S., Perry, B. D., Brissette, W. H., et al. (2003) · Science · doi:10.1126/science.1087061 · Cited by 607

Nonredundant roles for Stat5a/b in directly regulating Foxp3

Yao, Z., Kanno, Y., Kerenyi, M. A., Stephens, G. L., Durant, L. R., Watford, W. T., Laurence, A. D. J., Robinson, G. W., Shevach, E. M., Moriggl, R., et al. (2007) · Blood · doi:10.1182/blood-2006-11-055756 · Cited by 592

Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia

Harvey, R. C., Mullighan, C. G., Chen, I., Wharton, W., Mikhail, F. M., Carroll, A. J., Kang, H., Liu, W., Dobbin, K. K., Smith, M. A., et al. (2010) · Blood · doi:10.1182/blood-2009-09-245944 · Cited by 568

JAK mutations in high-risk childhood acute lymphoblastic leukemia

Mullighan, C. G., Zhang, J., Harvey, R. C., Collins-Underwood, J. R., Schulman, B. A., Phillips, L. A., Tasian, S. K., Loh, M. L., Su, X., Liu, W., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0811761106 · Cited by 558

Constitutively activated Jak-STAT pathway in T cells transformed with HTLV-I

Migone, T.-S., Lin, J.-X., Cereseto, A., Mulloy, J. C., O'Shea, J. J., Franchini, G., & Leonard, W. J. (1995) · Science · doi:10.1126/science.7604283 · Cited by 557

Exploiting Synthetic Lethality for the Therapy of ABC Diffuse Large B Cell Lymphoma

Yang, Y., Shaffer, A. L., Emre, N. C. T., Ceribelli, M., Zhang, M., Wright, G. W., Xiao, W., Powell, J. I., Platig, J., Kohlhammer, H., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.05.024 · Cited by 541

Growth Hormone Insensitivity Associated with a STAT5b Mutation

Kofoed, E. M., Hwa, V., Little, B. M., Woods, K. A., Buckway, C. K., Tsubaki, J., Pratt, K. L., Bezrodnik, L., Jasper, H., Tepper, A., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022926 · Cited by 522

Impairment of Mycobacterial But Not Viral Immunity by a Germline Human STAT1 Mutation

Boisson‐Dupuis, S., Dargemont, C., Fieschi, C., Thomassin, N., Rosenzweig, S. D., Harris, J., Holland, S. M., Schreiber, R. D., & Casanova, J. (2001) · Science · doi:10.1126/science.1061154 · Cited by 517

Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia

Russell, L. J., Capasso, M., Vater, I., Akasaka, T., Bernard, O., Calasanz, M. J., Chandrasekaran, T., Chapiro, É., Gesk, S., Griffiths, M., et al. (2009) · Blood · doi:10.1182/blood-2009-03-208397 · Cited by 498

Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours

Rebouissou, S., Amessou, M., Couchy, G., Poussin, K., Imbeaud, S., Pilati, C., Izard, T., Balabaud, C., Bioulac-Sage, P., & Zucman-Rossi, J. (2009) · Nature · doi:10.1038/nature07475 · Cited by 477

Mutations in STAT3 and IL12RB1 impair the development of human IL-17–producing T cells

de Beaucoudrey, L., Puel, A., Filipe‐Santos, O., Cobat, A., Ghandil, P., Chrabieh, M., Feinberg, J. M., von Bernuth, H., Samarina, A., Jannière, L., et al. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20080321 · Cited by 448

Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia

Zenatti, P. P., Ribeiro, D., Li, W., Zuurbier, L. C., da Silva, M. C., Paganin, M., Tritapoe, J. M., Hixon, J. A., Silveira, A. B., Cardoso, B. A., et al. (2011) · Nature Genetics · doi:10.1038/ng.924 · Cited by 426

Physiological Jak2V617F Expression Causes a Lethal Myeloproliferative Neoplasm with Differential Effects on Hematopoietic Stem and Progenitor Cells

Mullally, A., Lane, S., Ball, B. J., Megerdichian, C., Okabe, R. O., Al‐Shahrour, F., Paktinat, M., Haydu, J. E., Housman, E., Lord, A. M., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.05.015 · Cited by 411

JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms

Jones, A. V., Chase, A., Silver, R. T., Oscier, D. G., Zoi, K., Wang, Y. L., Cario, H., Pahl, H. L., Collins, A. R., Reiter, A., et al. (2009) · Nature Genetics · doi:10.1038/ng.334 · Cited by 407

STAT signaling in head and neck cancer

Song, J. I., & Grandis, J. R. (2000) · Oncogene · doi:10.1038/sj.onc.1203483 · Cited by 374

Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-κB pathways in subtypes of diffuse large B-cell lymphoma

Lam, L. T., Wright, G. W., Davis, R. E., Lenz, G., Farinha, P., Dang, L., Chan, J. W., Rosenwald, A., Gascoyne, R. D., & Staudt, L. M. (2007) · Blood · doi:10.1182/blood-2007-09-111948 · Cited by 366

A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms

Olcaydu, D., Harutyunyan, A. S., Jäger, R., Berg, T., Gisslinger, B., Pabinger, I., Gisslinger, H., & Královics, R. (2009) · Nature Genetics · doi:10.1038/ng.341 · Cited by 361

Genomics and the Multifactorial Nature of Human Autoimmune Disease

Cho, J. H., & Gregersen, P. K. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1100030 · Cited by 360

A germline JAK2 SNP is associated with predisposition to the development of JAK2V617F-positive myeloproliferative neoplasms

Kilpivaara, O., Mukherjee, S., Schram, A. M., Wadleigh, M., Mullally, A., Ebert, B. L., Bass, A. J., Marubayashi, S., Heguy, A., Garcia‐Manero, G., et al. (2009) · Nature Genetics · doi:10.1038/ng.342 · Cited by 357

Meta-analysis of genome-wide association studies identifies three new risk loci for atopic dermatitis

Paternoster, L., Standl, M., Chen, C., Ramasamy, A., Bønnelykke, K., Duijts, L., Ferreira, M. A. R., Alves, A. C., Thyssen, J. P., Albrecht, E., et al. (2011) · Nature Genetics · doi:10.1038/ng.1017 · Cited by 351

Gain-of-function mutations in interleukin-7 receptor-α ( IL7R ) in childhood acute lymphoblastic leukemias

Shochat, C., Tal, N., Bandapalli, O. R., Palmi, C., Ganmore, I., Kronnie, G. T., Cario, G., Cazzaniga, G., Kulozik, A. E., Stanulla, M., et al. (2011) · The Journal of Experimental Medicine · doi:10.1084/jem.20110580 · Cited by 348

Autosomal Dominant STAT3 Deficiency and Hyper-IgE Syndrome

Chandesris, M., Melki, I., Natividad, A., Puel, A., Fieschi, C., Ling, Y., Thumerelle, C., Oksenhendler, É., Boutboul, D., Thomas, C., et al. (2012) · Medicine · doi:10.1097/md.0b013e31825f95b9 · Cited by 346

Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study

Papp, K. A., Menter, A., Strober, B. E., Langley, R. G. B., Buonanno, M., Wolk, R. A., Gupta, P. K., Krishnaswami, S., Tan, H., & Harness, J. A. (2012) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2012.11168.x · Cited by 337

Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia

Yoda, A., Yoda, Y., Chiaretti, S., Bar‐Natan, M., Mani, K. M., Rodig, S. J., West, N. H., Xiao, Y., Brown, J. R., Mitsiades, C. S., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0911726107 · Cited by 336

Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome

Bercovich, D., Ganmore, I., Scott, L. M., Wainreb, G., Birger, Y., Elimelech, A., Shochat, C., Cazzaniga, G., Biondi, A., Basso, G., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61341-0 · Cited by 335

Inborn Errors of Human JAKs and STATs

Casanova, J., Holland, S. M., & Notarangelo, L. D. (2012) · Immunity · doi:10.1016/j.immuni.2012.03.016 · Cited by 333

Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia

Flex, E., Petrangeli, V., Stella, L., Chiaretti, S., Hornakova, T., Knoops, L., Ariola, C., Fodale, V., Clappier, E., Paoloni, F. P., et al. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20072182 · Cited by 331

Stat5b Is Essential for Natural Killer Cell–mediated Proliferation and Cytolytic Activity

Imada, K., Bloom, E. T., Nakajima, H., Horvath‐Arcidiacono, J. A., Udy, G. B., Davey, H. W., & Leonard, W. J. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.11.2067 · Cited by 325

Higher response to lenalidomide in relapsed/refractory diffuse large B‐cell lymphoma in nongerminal center B‐cell–like than in germinal center B‐cell–like phenotype

Hernandez‐Ilizaliturri, F. J., Deeb, G., Zinzani, P. L., Pileri, S. A., Malik, F., Macon, W. R., Goy, A. H., Witzig, T. E., & Czuczman, M. S. (2011) · Cancer · doi:10.1002/cncr.26135 · Cited by 304

Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas

Ding, B. B., Yu, J., Yu, R. Y.-L., Mendez, L., Shaknovich, R., Zhang, Y., Cattoretti, G., & Ye, B. H. (2007) · Blood · doi:10.1182/blood-2007-04-087734 · Cited by 301

Inborn errors of human STAT1: allelic heterogeneity governs the diversity of immunological and infectious phenotypes

Boisson‐Dupuis, S., Kong, X., Okada, S., Cypowyj, S., Puel, A., Abel, L., & Casanova, J. (2012) · Current Opinion in Immunology · doi:10.1016/j.coi.2012.04.011 · Cited by 293

Cooperative Epigenetic Modulation by Cancer Amplicon Genes

Rui, L., Emre, N. C. T., Kruhlak, M. J., Chung, H., Steidl, C., Slack, G. W., Wright, G. W., Lenz, G., Ngo, V. N., Shaffer, A. L., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.11.013 · Cited by 288

A Critical Role for STAT3 Transcription Factor Signaling in the Development and Maintenance of Human T Cell Memory

Siegel, A., Heimall, J. R., Freeman, A. F., Hsu, A. P., Brittain, E., Brenchley, J. M., Douek, D. C., Fahle, G. H., Cohen, J. I., Holland, S. M., et al. (2011) · Immunity · doi:10.1016/j.immuni.2011.09.016 · Cited by 284

The pseudokinase domain of JAK2 is a dual-specificity protein kinase that negatively regulates cytokine signaling

Ungureanu, D., Wu, J., Pekkala, T., Niranjan, Y., Young, C., Jensen, O. N., Xu, C., Neubert, T. A., Skoda, R. C., Hubbard, S. R., et al. (2011) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2099 · Cited by 277

Janus Kinase 3–Activating Mutations Identified in Natural Killer/T-cell Lymphoma

Koo, G. C., Tan, S., Tang, T. P. L., Poon, S. L., Allen, G. E., Tan, L. H. C., Chong, S. C., Ong, W. S., Tay, K. K. W., Tao, M., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0028 · Cited by 277

Interleukin 13 Is Secreted by and Stimulates the Growth of Hodgkin and Reed-Sternberg Cells

Kapp, U., Yeh, W., Patterson, B. J., Elia, A., Kägi, D., Ho, A., Hessel, A., Tipsword, M., Williams, A., Mirtsos, C., et al. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.12.1939 · Cited by 274

Crystal structures of the JAK2 pseudokinase domain and the pathogenic mutant V617F

Bandaranayake, R. M., Ungureanu, D., Shan, Y., Shaw, D. E., Silvennoinen, O., & Hubbard, S. R. (2012) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2348 · Cited by 261

Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24 577 first-degree relatives of 11 039 patients with myeloproliferative neoplasms in Sweden

Landgren, O., Goldin, L. R., Kristinsson, S. Y., Helgadottir, E. A., Samuelsson, J., & Björkholm, M. (2008) · Blood · doi:10.1182/blood-2008-03-143602 · Cited by 257

JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F–positive essential thrombocythemia

Li, J., Spensberger, D., Ahn, J. S., Anand, S., Beer, P. A., Ghevaert, C., Chen, E., Forrai, A., Scott, L. M., Ferreira, R., et al. (2010) · Blood · doi:10.1182/blood-2009-12-259747 · Cited by 212

Specific JAK2 mutation (JAK2R683) and multiple gene deletions in Down syndrome acute lymphoblastic leukemia

Kearney, L., de Castro, D. G., Yeung, J., Procter, J., Horsley, S. W., Eguchi‐Ishimae, M., Bateman, C. M., Anderson, K., Chaplin, T., Young, B. D., et al. (2008) · Blood · doi:10.1182/blood-2008-08-170928 · Cited by 187

A partial form of recessive STAT1 deficiency in humans

Chapgier, A. L. A., Kong, X., Boisson‐Dupuis, S., Jouanguy, E., Averbuch, D., Feinberg, J. M., Zhang, S., Bustamante, J. C., Vogt, G., Lejeune, J., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37083 · Cited by 187

Essential role for Stat5a/b in myeloproliferative neoplasms induced by BCR-ABL1 and JAK2V617F in mice

Walz, C., Ahmed, W. B., Lazarides, K., Betancur, M., Patel, N. K., Hennighausen, L. G., Zaleskas, V. M., & Etten, R. A. V. (2012) · Blood · doi:10.1182/blood-2011-12-397554 · Cited by 179

Activating L265P mutations of the MYD88 gene are common in primary central nervous system lymphoma

Montesinos‐Rongen, M., Godlewska, E., Brunn, A., Wiestler, O. D., Siebert, R., & Deckert, M. (2011) · Acta Neuropathologica · doi:10.1007/s00401-011-0891-2 · Cited by 178

A genome-wide association study of plasma total IgE concentrations in the Framingham Heart Study

Granada, M., Wilk, J. B., Tuzova, M. N., Strachan, D. P., Weidinger, S., Albrecht, E., Gieger, C., Heinrich, J., Himes, B. E., Hunninghake, G. M., et al. (2011) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2011.09.029 · Cited by 166

The novel JAK inhibitor AZD1480 blocks STAT3 and FGFR3 signaling, resulting in suppression of human myeloma cell growth and survival

Scuto, A., Krejčı́, P., Popplewell, L. L., Wu, J., wang, Y., Kujawski, M., Kowolik, C. M., Xin, H., Chen, L., Wang, Y., et al. (2010) · Leukemia · doi:10.1038/leu.2010.289 · Cited by 140

Critical requirement for Stat5 in a mouse model of polycythemia vera

Yan, D., Hutchison, R. E., & Mohi, G. (2011) · Blood · doi:10.1182/blood-2011-03-345215 · Cited by 132

Janus kinase deregulation in leukemia and lymphoma

Chen, E., Staudt, L. M., & Green, A. R. (2012) · Immunity · doi:10.1016/j.immuni.2012.03.017 · Cited by 123

Identification of somatic JAK1 mutations in patients with acute myeloid leukemia.

Xiang, Z.-F., Zhao, Y., Mitaksov, V., Fremont, D., Kasai, Y., Molitoris, A., Ries, R., Miner, T., McLellan, M., Dipersio, J., et al. (2008) · Blood · doi:10.1182/blood-2007-05-090308 · Cited by 108

A Patient with Tyrosine Kinase 2 Deficiency without Hyper-IgE Syndrome

Kılıç, S. Ş., HACIMUSTAFAOĞLU, M. K., Boisson‐Dupuis, S., Kreins, A. Y., Grant, A. V., Abel, L., & Casanova, J. (2012) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2012.01.056 · Cited by 108

BCR and TLR signaling pathways are recurrently targeted by genetic changes in splenic marginal zone lymphomas

Yan, Q., Huang, Y., Watkins, J. A., Kocialkowski, S., Zeng, N., Hamoudi, R., Isaacson, P. G., de Leval, L., Wotherspoon, A. C., & Du, M. (2011) · Haematologica · doi:10.3324/haematol.2011.054080 · Cited by 99

Granulocyte colony-stimulating factor receptor mutations in severe congenital neutropenia transforming to acute myelogenous leukemia confer resistance to apoptosis and enhance cell survival

Hunter, M. G., & Avalos, B. R. (2000) · Blood · doi:10.1182/blood.v95.6.2132 · Cited by 90

Prediction of the structure of human Janus kinase 2 (JAK2) comprising JAK homology domains 1 through 7

Giordanetto, F., & Kroemer, R. T. (2002) · Protein Engineering Design and Selection · doi:10.1093/protein/15.9.727 · Cited by 88

FERM domain mutations induce gain of function in JAK3 in adult T-cell leukemia/lymphoma

Elliott, N., Cleveland, S. M., Grann, V. R., Janik, J. E., Waldmann, T. A., & Davé, U. P. (2011) · Blood · doi:10.1182/blood-2010-12-319467 · Cited by 86

STAT5 Activation Is Critical for the Transformation Mediated by Myeloproliferative Disorder-associated JAK2 V617F Mutant

Funakoshi‐Tago, M., Tago, K., Abe, M., Sonoda, Y., & Kasahara, T. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.040733 · Cited by 81

A Chemical Biology Approach to Developing STAT Inhibitors: Molecular Strategies for Accelerating Clinical Translation

Nelson, E. A., Sharma, S. V., Settleman, J. E., & Frank, D. A. (2011) · Oncotarget · doi:10.18632/oncotarget.296 · Cited by 76

A Novel STAT1 Mutation Associated with Disseminated Mycobacterial Disease

Sampaio, E. P., Bax, H. I., Hsu, A. P., Kristosturyan, E., Pechacek, J., Chandrasekaran, P., Paulson, M. L., Dias, D. L., Spalding, C. D., Uzel, G., et al. (2012) · Journal of Clinical Immunology · doi:10.1007/s10875-012-9659-2 · Cited by 72

JAK1 mutations are not frequent events in adult T‐ALL: a GRAALL study

Asnafi, V., Noir, S. L., Lhermitte, L., Gardin, C., Legrand, F., Vallantin, X., Malfuson, J., Ifrah, N., Dombret, H., & Macintyre, E. A. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07912.x · Cited by 48

Tyrosine kinase pathways modulate tumor susceptibility to natural killer cells

Bellucci, R., Nguyen, H.-N. P., Martin, A. M., Heinrichs, S., Schinzel, A. C., Hahn, W. C., & Ritz, J. (2012) · Journal of Clinical Investigation · doi:10.1172/jci58457 · Cited by 34

Cytokines

O’Shea, J. J., Sims, J., Siegel, R. M., & Farber, J. M. (2011) · Elsevier eBooks · doi:10.1016/b978-0-323-06551-1.00011-7 · Cited by 1

The JAK/STAT signaling pathway: from bench to clinic

Hu, X., li, J., Fu, M., Zhao, X., & Wang, W. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00791-1 · Cited by 2,633

The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY

Harding, S. D., Sharman, J. L., Faccenda, E., Southan, C., Pawson, A. J., Ireland, S. M., Gray, A. J. G., Bruce, L., Alexander, S. P. H., Anderton, S. M., et al. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx1121 · Cited by 1,650

The JAK-STAT Pathway: Impact on Human Disease and Therapeutic Intervention

O’Shea, J. J., Schwartz, D. M., Villarino, A. V., Gadina, M., McInnes, I. B., & Laurence, A. D. J. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-051113-024537 · Cited by 1,670

Activated STING in a Vascular and Pulmonary Syndrome

Liu, Y., de Jesus, A. A., Marrero, B., Yang, D., RAMSEY, S. E., Sanchez, G. A. M., Tenbrock, K., Wittkowski, H., Jones, O. Y., Kuehn, H. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1312625 · Cited by 1,415

JAK inhibition as a therapeutic strategy for immune and inflammatory diseases

Schwartz, D. M., Kanno, Y., Villarino, A., Ward, M., Gadina, M., & O'Shea, J. J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.201 · Cited by 1,266

JAKs—STATs信号传导——疾病治疗新领域

Ping, Z. X. (2001) · 国外医学（免疫学分册）

004 JAKs-STATs信号传导--疾病治疗新领域

Ping, Z. X., & 吴慧君 (2001) · 国外医学（免疫学分册） · doi:10.3760/cma.j.issn.1673-4394.2001.01.004

Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer

Chen, X., Yao, Q., Gu, X., Shi, Q., Yuan, X., Chu, Q., Bao, Z., Lu, J., & Li, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01468-7 · Cited by 797

JAKs and STATs from a Clinical Perspective: Loss-of-Function Mutations, Gain-of-Function Mutations, and Their Multidimensional Consequences

Ott, N., Faletti, L. E., Heeg, M., Andreani, V., & Grimbacher, B. (2023) · Journal of Clinical Immunology · doi:10.1007/s10875-023-01483-x · Cited by 87

Immunodeficiency: Consequences of Mutations in JAK-STAT Signaling

Silberger, D. J., & Pham, D. (2020) · CRC Press eBooks · doi:10.1201/9781351042468-13 · Cited by 1